Dr. Nicholas J. Vogelzang, M.D., FACP, served as the Head of Genitourinary Cancer Program and Associate Center Director for Clinical Research at Nevada Cancer Institute since 2009. Dr. Vogelzang is a Professor of medicine at the University of Nevada School of Medicine. He was a Professor of Medicine and Surgery (Urology) and the Buffet Chair in Genitourinary Oncology of the University of Chicago, where he was faculty member from 1982 to 2003. He served as Institute Director at Nevada Cancer Institute. from 2004 to 2009 and served as its executive vice president for Academic Affairs since January 2008. In 2005, Dr. Vogelzang edited Malignant Mesothelioma, the leading research clinical textbook on the subject. Dr. Vogelzang sees and evaluates patients with prostate, kidney, bladder and testis cancer for second opinions, standard of care treatment and for entry onto clinical trials. He served as the Chairman of Mesothelioma Applied Research Foundation since August 2006 and serves as its Director. Dr. Vogelzang has been Member of Solid Tumor Advisory Board at Ambit Biosciences Corporation since February 28, 2008. He serves as a Member of Scientific Advisory Board of Caris Life Sciences, Inc. He serves as a Member of Scientific Advisory Board of Cougar Biotechnology, Inc. He served as a Member of the Medical Advisory Board at Wilex AG. He serves as Member of Scientific Advisory Board of Advanced Life Sciences Holdings, Inc. He served as a Director of Nevada Cancer Institute (NVCI) since January 2004. He served as a Director of American Society of Clinical Oncology from 1993 to 1996. Dr. Vogelzang has served on the board of directors for the American Cancer Society and the Editorial Review Board for Cancer Research. He served as Director of the University of Chicago Cancer Research Center. Dr. Vogelzang is a recognized expert in new therapies for patients with metastatic kidney cancer, including genetic therapy, new cytokine therapy, and combination cytokine therapy. He also conducts large-scale national trials in the field of prostate cancer and mesothelioma. He served as president of the Illinois Division of the American Cancer Society. Dr. Vogelzang was the principal investigator at the University of Chicago for Cancer and Leukemia Group B (CALGB) from 1988 to 1999, chair of the CALGB Prostate Committee from 1993 to 1999 and principal investigator of the University of Chicago Cancer Center Support Grant. He has over 250 publications and is the senior editor of the Comprehensive Textbook of Genitourinary Oncology. He has served on the Editorial Boards of Cancer, Cancer Research, Clinical Genitourinary Cancer, The Prostate Journal, Seminars in Oncology and the Journal of Clinical Oncology, and is a reviewer for numerous other journals. As a survivor of Hodgkin's disease, he is a sought-after public speaker. Dr. Vogelzang is the author of nearly 435 scientific publications (including peer-reviewed papers, internet publications, reviews, book chapters and books and journal issues), over 381 abstracts and letters, and has given over 350 scientific lectures. He is a member of many societies, including the American Association for Cancer Research, the American Society of Clinical Oncology, the American Urological Association, the Kidney Cancer Association, the Society of Urologic Oncology and the European Society for Medical Oncology. He completed his internship, residency and chief residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago, followed by his fellowship in medical oncology at the University of Minnesota in Minneapolis. Dr. Vogelzang received his M.D. from the University of Illinois at Chicago in 1974. 

 Oncology